Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis

Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis

Silo Plans to explore the use of Psychedelics to Target Inflammation

Englewood Cliffs NJ, March 04, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTC QB: SILO), a developmental stage biopharmaceutical company, today announced that it has executed an exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known as “Joint-homing peptides for use in the investigation and treatment of arthritogenic processes.”

The ability of the peptides to target inflamed endothelium suggests they could be used to target drug delivery to the diseased joints. This approach could enhance the therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug. These peptides have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. The peptides could also be customizable and used to deliver nanoparticles for precise imaging. In addition, these novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis.

“This option gives Silo access to a unique and potentially vital therapeutic that can also act as a drug delivery platform,” stated Eric Weisblum, Chairman and CEO of Silo Pharma. “The ability to deliver compounds directly to targeted areas of the body with this technology could be revolutionary by increasing the efficacy of the treatment while reducing the amount of medication needed. There is a tremendous need for creative and unique therapeutics for patients suffering from rare diseases.”

About Silo Pharma

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.  For more information, visit www.silopharma.com.

Safe Harbor and Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact: